WB | 1/1000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | Interleukin-22 receptor subunit alpha-1, IL-22 receptor subunit alpha-1, IL-22R-alpha-1, IL-22RA1, Cytokine receptor class-II member 9, Cytokine receptor family 2 member 9, CRF2-9, ZcytoR11, IL22RA1, IL22R |
Entrez GeneID | 58985 |
WB Predicted band size | 63.1kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | This IL22RA1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 408-436 amino acids from the C-terminal region of human IL22RA1. |
Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于假设的3篇关于IL22RA1抗体的参考文献示例(实际文献请通过学术数据库检索):
---
1. **文献名称**: *Structural Insights into IL22RA1 and IL-22 Interaction*
**作者**: Jones, A. et al. (2018)
**摘要**: 通过X射线晶体学解析IL22RA1与IL-22的复合物结构,揭示了受体-配体结合的关键结构域,为靶向抗体设计提供依据。
2. **文献名称**: *IL22RA1 Antibody Attenuates Colitis in Murine Models*
**作者**: Smith, B. et al. (2020)
**摘要**: 研究显示,抗IL22RA1单抗可抑制IL-22信号传导,减轻小鼠结肠炎模型的肠道炎症,提示其治疗炎症性肠病的潜力。
3. **文献名称**: *Targeting IL22RA1 in Colon Cancer via Therapeutic Antibodies*
**作者**: Chen, L. et al. (2021)
**摘要**: 开发靶向IL22RA1的人源化抗体,证明其通过阻断STAT3通路抑制结肠癌细胞增殖,并在异种移植模型中减少肿瘤生长。
---
**提示**:如需真实文献,建议使用关键词“IL22RA1 antibody”在PubMed或Google Scholar检索,筛选涉及信号机制、疾病模型或治疗应用的研究。
IL22RA1 (Interleukin-22 Receptor Subunit Alpha 1) is a key component of the heterodimeric receptor complex for IL-22. a cytokine belonging to the IL-10 family. This receptor subunit pairs with IL10Rβ to mediate IL-22 signaling, which primarily regulates epithelial and stromal cell responses in barrier tissues, including the skin, gut, and lungs. IL-22 plays dual roles in immunity, promoting tissue repair and mucosal defense while contributing to pathogenic inflammation in autoimmune or chronic conditions.
Antibodies targeting IL22RA1 are valuable tools for studying IL-22 signaling pathways and their involvement in diseases such as psoriasis, inflammatory bowel disease (IBD), and cancer. These antibodies, often monoclonal, are used to block receptor-ligand interactions, detect receptor expression in tissues (via techniques like Western blot, immunohistochemistry, or flow cytometry), or explore therapeutic strategies. For example, inhibiting IL22RA1 signaling has shown potential in preclinical models of psoriasis and colitis by reducing pro-inflammatory responses. Conversely, enhancing IL-22 activity via receptor modulation might aid in epithelial regeneration during injury or infection.
Research also links IL22RA1 overexpression to certain cancers, suggesting its role in tumor microenvironment regulation. However, therapeutic targeting requires caution due to IL-22's context-dependent effects. Current studies focus on optimizing antibody specificity and evaluating clinical efficacy, balancing anti-inflammatory benefits against risks of disrupting tissue homeostasis.
×